Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil for Prevention of Contrast-Induced Nephropathy in Diabetic Patients Undergoing Lower Extremity Arterial Intervention
ChiCTR-IPR-16008892Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Vasostenoon in contrast-induced nephropathy (CIN) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Serum creatinine, Serum and urinary bladder inhibition C and 4 more. Started Jul 2016; status: recruiting.
02
Drugs
Vasostenoon
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on ChiCTR-IPR-16008892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008892.